Variant · Expression
NCOA3 OVEREXPRESSION
CI-VAR-00003019Explore in graph →CIViC 205
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23322234
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Breast Neoplasm1 | ||||||||
| NCOA3 OVEREXPRESSION | (prognostic) | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID493High expression determined by immunohistochemistry of NCOA3 was found in 571 out of 1,836 breast cancer samples. Those with high expression had worse overall and disease-specific survival. PMID 23322234 · Burandt et al., 2013 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available